220 related articles for article (PubMed ID: 18291435)
1. Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity.
Su J; Willert C; Comanita L; Peters A; Gilbert PA; Strathdee C; O'Connell PJ; McFadden GD; Dekaban GA
Virology; 2008 May; 375(1):48-58. PubMed ID: 18291435
[TBL] [Abstract][Full Text] [Related]
2. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
Li W; Li S; Hu Y; Tang B; Cui L; He W
Vaccine; 2008 Jun; 26(26):3282-90. PubMed ID: 18472194
[TBL] [Abstract][Full Text] [Related]
3. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
Cukalac T; Moffat JM; Venturi V; Davenport MP; Doherty PC; Turner SJ; Stambas J
Vaccine; 2009 Nov; 27(48):6755-61. PubMed ID: 19744584
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
[TBL] [Abstract][Full Text] [Related]
5. [Immune response to HIV-2 gp105 DNA vaccine in mice].
Li ZJ; Jin NY; Jiang WZ; Zhang LS
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jan; 21(1):86-9. PubMed ID: 15629093
[TBL] [Abstract][Full Text] [Related]
6. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
7. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
8. Immunization of neonatal mice with LAMP/p55 HIV gag DNA elicits robust immune responses that last to adulthood.
Rigato PO; Maciel M; Goldoni AL; Piubelli O; de Brito CA; Fusaro AE; Eurico de Alencar LX; August T; Azevedo Marques ET; da Silva Duarte AJ; Sato MN
Virology; 2010 Oct; 406(1):37-47. PubMed ID: 20667577
[TBL] [Abstract][Full Text] [Related]
9. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.
Ko SY; Cheng C; Kong WP; Wang L; Kanekiyo M; Einfeld D; King CR; Gall JG; Nabel GJ
J Virol; 2009 Jan; 83(2):748-56. PubMed ID: 18987146
[TBL] [Abstract][Full Text] [Related]
10. DNA vaccine expressing HIV-1 gp120/immunoglobulin fusion protein enhances cellular immunity.
Shimada M; Yoshizaki S; Jounai N; Kondo A; Ichino M; Ryo A; Okuda K
Vaccine; 2010 Jul; 28(31):4920-7. PubMed ID: 20566393
[TBL] [Abstract][Full Text] [Related]
11. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
[TBL] [Abstract][Full Text] [Related]
12. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine.
Wingard JB; Anderson B; Weissman D
Eur J Immunol; 2008 May; 38(5):1310-20. PubMed ID: 18412164
[TBL] [Abstract][Full Text] [Related]
13. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
Wang X; Uto T; Akagi T; Akashi M; Baba M
J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
15. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
Hovav AH; Cayabyab MJ; Panas MW; Santra S; Greenland J; Geiben R; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2007 Jan; 81(1):74-83. PubMed ID: 17050608
[TBL] [Abstract][Full Text] [Related]
16. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
Akahata W; Yang ZY; Nabel GJ
J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
[TBL] [Abstract][Full Text] [Related]
17. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.
Rasmussen RA; Ong H; Kittel C; Ruprecht CR; Ferrantelli F; Hu SL; Polacino P; McKenna J; Moon J; Travis B; Ruprecht RM
Vaccine; 2006 Mar; 24(13):2324-32. PubMed ID: 16406147
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
19. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses.
Gzyl J; Bolesta E; Wierzbicki A; Kmieciak D; Naito T; Honda M; Komuro K; Kaneko Y; Kozbor D
Virology; 2004 Jan; 318(2):493-506. PubMed ID: 14972518
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
